gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

CD274 molecule

PD-L1, B7-H1
Top mentioned proteins: CAN, CTLA-4, CD8, HAD, CD4
Papers using PD-L1 antibodies
Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)
Supplier
Dosch H.-Michael et al., In Diabetes, 2006
... Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models ...
Clearance of Chlamydia trachomatis from the murine genital mucosa does not require perforin-mediated cytolysis or Fas-mediated apoptosis
Supplier
Zhong Guangming et al., In BMC Infectious Diseases, 1998
... San Diego, CA) on days 0 (the same day of infection), 2 and 4, 200 μg of anti-PD-L1 (clone 10 F.9 G2, Rat IgG2b, cat#124309, Biolegend, San Diego, CA) on ...
Papers on PD-L1
Tolerogenic Effect of Mouse Fibroblasts on Dendritic Cells.
New
Ghahary et al., Vancouver, Canada. In Immunology, Feb 2016
The results of our in vitro study showed that both co-inhibitory (PD-L1, PD-L2 and B7H4) and co-stimulatory (CD86) molecules were up-regulated when DCs were co-cultured with fibroblasts.
A lack of Fas/FasL signalling leads to disturbances in the antiviral response during ectromelia virus infection.
New
Krzyzowska et al., Warsaw, Poland. In Arch Virol, Feb 2016
Furthermore, at days 7 and 10 of the infection, we observed significantly higher numbers of PD-L1-expressing dendritic cells in Fas (-) and FasL (-) mice in comparison to wild-type mice.
Programmed Death Ligand 1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
New
Yatabe et al., Nagoya, Japan. In Arch Pathol Lab Med, Feb 2016
UNASSIGNED: The binding of programmed death ligands 1 and 2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor.
Cutting Edge: MicroRNA-223 Regulates Myeloid Dendritic Cell-Driven Th17 Responses in Experimental Autoimmune Encephalomyelitis.
New
Miller et al., Chicago, United States. In J Immunol, Feb 2016
Knockout mDCs have increased PD-L1 and decreased IL-1β, IL-6, and IL-23 expression, as well as a reduced capacity to drive Th17, but not Th1, cell differentiation.
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Review
New
Wu et al., Guangzhou, China. In Tumour Biol, Feb 2016
UNASSIGNED: Programmed cell death protein-1 (PD-1) and ligand (PD-L1) provide an important escape mechanism from immune attack, and blockade therapy of these proteins show promising clinical benefits in many types of cancer.
Regulation of Immunity by Butyrophilins.
New
Impact
Trowsdale et al., Cambridge, United Kingdom. In Annu Rev Immunol, Feb 2016
They are considered to be members of the B7 family of costimulatory receptors, which includes B7.1 (CD80), B7.2 (CD86), and related molecules, such as PD-L1 (B7-H1, CD274), ICOS-L (CD275), and B7-H3 (CD276).
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
New
Impact
Powles et al., Boston, United States. In J Clin Oncol, Feb 2016
PURPOSE: The objective was to determine the safety and clinical activity of atezolizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma (RCC).
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Review
New
Lambotte et al., Villejuif, France. In Eur J Cancer, Feb 2016
The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand PD-L1.
PD-L1-specific T cells.
Review
New
Andersen et al., Copenhagen, Denmark. In Cancer Immunol Immunother, Feb 2016
UNASSIGNED: Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies.
Immunotherapy of melanoma: efficacy and mode of action.
Review
New
Röcken et al., Tübingen, Germany. In J Dtsch Dermatol Ges, Jan 2016
These "immune checkpoint inhibitors" are directed against immune inhibitory molecules, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1).
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
New
Impact
Garon et al., New Haven, United States. In Lancet, Jan 2016
We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Updates in Therapy for Advanced Melanoma.
Review
New
Salama et al., Durham, United States. In Cancers (basel), Dec 2015
The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development.
T cells from patients with Candida sepsis display a suppressive immunophenotype.
New
Hotchkiss et al., Saint Louis, United States. In Crit Care, Dec 2015
CD4 and CD8 T cells from patients with Candidemia expressed markers typical of T cell exhaustion as indicated by either increased percentages of or increased MFI for programmed cell death 1 (PD-1) or its ligand (PD-L1).
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
New
Impact
Gajewski et al., Chicago, United States. In Science, Dec 2015
Oral administration of Bifidobacterium alone improved tumor control to the same degree as programmed cell death protein 1 ligand 1 (PD-L1)-specific antibody therapy (checkpoint blockade), and combination treatment nearly abolished tumor outgrowth.
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
New
Impact
Zou et al., Ann Arbor, United States. In Nature, Dec 2015
Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice.
Innate IFN-γ is essential for programmed death ligand-1-mediated T cell stimulation following Listeria monocytogenes infection.
GeneRIF
Way et al., Minneapolis, United States. In J Immunol, 2012
Transgenic PDL-1 blockade initiated prior to induction of listeriosis infection blunts pathogen-specific CD8-positive T cell expansion in mice with targeted interferon-gamma defects.
B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.
GeneRIF
Jayat-Vignoles et al., Limoges, France. In J Immunol, 2012
B7-H1 suppresses killing of Epstein-Barr virus-immortalized B cells by their autologous T and natural killer (NK) cells.
Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
GeneRIF
Jensen et al., Duarte, United States. In Mol Immunol, 2012
Cell surface expressed PD1:CD28 retains the capacity to bind PD-L1 resulting in T cell costimulation.
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.
Impact
GeneRIF
O'Shea et al., Bethesda, United States. In Immunity, 2012
IL-27-dependent induction of PD-L1 on naive cells inhibited IL-17 production in an untreated population of differentiating Th17 cells. Th17-cell-mediated autoimmune encephalomyelitis was lessened by IL-27-treated PD-L1 T-cells.
IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells.
GeneRIF
Thomson et al., Pittsburgh, United States. In J Immunol, 2012
IL-27 promotes cell surface expression of B7-H1 (Cd274) in liver plasmacytoid DCs (pDCs), which in turn increases the incidence of CD4+ T cells expressing Foxp3.
share on facebooktweetadd +1mail to friends